Last reviewed · How we verify
donor derived cytomegalovirus specific T lymphocytes
donor derived cytomegalovirus specific T lymphocytes is a Biologic drug developed by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. It is currently FDA-approved. Also known as: cytomegalovirus specific T lymphocytes.
At a glance
| Generic name | donor derived cytomegalovirus specific T lymphocytes |
|---|---|
| Also known as | cytomegalovirus specific T lymphocytes |
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Donor-Derived Viral Specific T-cells (VSTs) (PHASE1, PHASE2)
- CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency (NA)
- Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells (PHASE1)
- Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy (PHASE2)
- CMV-CTL for the Treatment of CMV Infection After HSCT (PHASE4)
- Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection (PHASE1, PHASE2)
- Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
- CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- donor derived cytomegalovirus specific T lymphocytes CI brief — competitive landscape report
- donor derived cytomegalovirus specific T lymphocytes updates RSS · CI watch RSS
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine portfolio CI
Frequently asked questions about donor derived cytomegalovirus specific T lymphocytes
What is donor derived cytomegalovirus specific T lymphocytes?
donor derived cytomegalovirus specific T lymphocytes is a Biologic drug developed by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.
Who makes donor derived cytomegalovirus specific T lymphocytes?
donor derived cytomegalovirus specific T lymphocytes is developed and marketed by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (see full Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine pipeline at /company/shanghai-general-hospital-shanghai-jiao-tong-university-school-of-medicine).
Is donor derived cytomegalovirus specific T lymphocytes also known as anything else?
donor derived cytomegalovirus specific T lymphocytes is also known as cytomegalovirus specific T lymphocytes.
What development phase is donor derived cytomegalovirus specific T lymphocytes in?
donor derived cytomegalovirus specific T lymphocytes is FDA-approved (marketed).
Related
- Manufacturer: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine — full pipeline
- Also known as: cytomegalovirus specific T lymphocytes
- Compare: donor derived cytomegalovirus specific T lymphocytes vs similar drugs
- Pricing: donor derived cytomegalovirus specific T lymphocytes cost, discount & access